Saudi Arabia Active Pharmaceutical Ingredients Market Forecasts & Opportunities Report 2024-2025 & 2030 Featuring Pfizer, Aurobindo Pharma, Novartis, BASF, Viatris, and Novo Nordisk
The Active Pharmaceutical Ingredients (API) market in Saudi Arabia is a critical segment of the country's pharmaceutical industry, which is experiencing notable expansion. This growth is fueled by rising healthcare needs, substantial government investment, and a shift toward enhancing local manufacturing capabilities. As one of the largest pharmaceutical markets in the Middle East, Saudi Arabia is integral to the regional API supply chain, both as a consumer and a producer.
Saudi Arabian Active Pharmaceutical Ingredients Market
Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Active Pharmaceutical Ingredients Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Saudi Arabia Active Pharmaceutical Ingredients Market was valued at USD 290.75 Million in 2024, and is expected to reach USD 417.62 Million by 2030, rising at a CAGR of 6.18%.
The demand for APIs is driven by the increasing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, which necessitate both essential and specialized pharmaceutical products. Additionally, the growing adoption of generic drugs is stimulating API production, as generics typically rely on more cost-effective active ingredients compared to branded drugs.
This trend is further supported by government policies that encourage the use of generics to reduce healthcare costs and improve access to medications. The regulatory landscape, overseen by the Saudi Food and Drug Authority (SFDA), ensures that all APIs meet international standards of quality, safety, and efficacy. The SFDA's rigorous regulations foster a controlled and high-quality manufacturing environment, which is essential for long-term market stability and growth.Key Market Drivers
Rising Healthcare Demand and Disease PrevalenceRising healthcare demand and increasing disease prevalence are critical factors driving the growth of the Active Pharmaceutical Ingredients (API) market in Saudi Arabia. As the Kingdom experiences significant demographic changes and the healthcare needs of its population grow, the demand for APIs is expanding in tandem. These factors create a pressing need for pharmaceuticals to address the rising incidence of chronic diseases, thus spurring a substantial market for both essential and specialized APIs. Saudi Arabia's population is steadily increasing, alongside a marked rise in life expectancy. With a growing and aging population, the demand for healthcare services is escalating.Government Initiatives and Policy SupportGovernment initiatives and policy support play a pivotal role in driving the growth of the Active Pharmaceutical Ingredients (API) market in Saudi Arabia. Saudi Arabia's Vision 2030 places a strong emphasis on healthcare workforce development to build a sustainable healthcare system.The National Transformation Program, a critical component of Vision 2030, directly supports the pharmaceutical sector by improving healthcare services and fostering innovation. The NTP includes goals for enhancing healthcare access, improving the quality of medical treatments, and expanding the capacity for drug production within the Kingdom.The Saudi Food and Drug Authority (SFDA) plays a crucial role in regulating the pharmaceutical sector, ensuring that all products, including APIs, meet international quality and safety standards. In recent years, the SFDA has made significant strides in streamlining regulatory processes to facilitate the entry of new players into the API market. These reforms are designed to ensure efficiency, reduce bureaucratic hurdles, and create an environment conducive to investment.Shift Toward Generic MedicinesThe shift toward generic medicines is a significant driver of growth in the Saudi Arabian Active Pharmaceutical Ingredients (API) market. This shift is reshaping the pharmaceutical landscape in the Kingdom, creating increased demand for high-quality, cost-effective APIs that form the backbone of generic drug production. Several factors are contributing to this transition, including government policies, cost-saving measures, and the evolving preferences of healthcare providers and consumers. Generic medicines are widely recognized for their cost-effectiveness compared to branded drugs.This growing demand for generics translates directly into a higher need for APIs, as these drugs rely heavily on active ingredients that are less expensive than their branded counterparts. As the Saudi healthcare system increasingly prioritizes affordability and access, the demand for APIs to produce generics continues to grow. The Saudi government has been a strong proponent of increasing the use of generic drugs in the Kingdom as part of its broader healthcare reform agenda. Policies designed to enhance access to affordable medicines have encouraged the use of generics, both in the public and private sectors.Key Market Challenges
Dependence on Imported Raw Materials and TechnologyOne of the most significant challenges facing the Saudi Arabian API market is the heavy reliance on imported raw materials and technology. While the Kingdom has made strides in promoting local pharmaceutical manufacturing, a large portion of the active ingredients used in the production of both branded and generic medicines is still imported from countries like India, China, and Europe. This dependency on foreign suppliers creates vulnerabilities in the supply chain, including fluctuations in raw material prices, geopolitical risks, and issues related to international trade.Regulatory and Compliance ChallengesThe Saudi Arabian pharmaceutical industry, including the API market, is subject to stringent regulatory frameworks governed by the Saudi Food and Drug Authority (SFDA). While these regulations are designed to ensure safety, efficacy, and quality, they can also pose significant challenges to API manufacturers. The regulatory requirements for API production are complex and often involve lengthy approval processes, particularly for new products or for generics that are being introduced to the market.Another issue is the harmonization of Saudi regulations with international standards. While Saudi Arabia is increasingly aligning its pharmaceutical regulations with global best practices, differences between local and international regulatory requirements can lead to delays and additional costs for API producers, especially those who wish to export their products. Regulatory complexity, coupled with a lack of clear guidance in some areas, continues to be a significant barrier to the growth of the Saudi API market.Key Market Trends
Increased Focus on Biotechnology and BiopharmaceuticalsOne of the most prominent trends influencing the future of the Saudi Arabian API market is the growing emphasis on biotechnology and biopharmaceuticals. With advancements in biologics and biosimilars, the pharmaceutical industry is experiencing a shift from traditional small-molecule drugs to more complex biologic treatments. These biologic drugs, which include monoclonal antibodies, recombinant proteins, and gene therapies, rely on specialized APIs that require advanced manufacturing processes and cutting-edge technology.As Saudi Arabia moves towards improving its healthcare system and expanding access to modern treatments, the demand for biologic drugs is anticipated to rise. This trend is already visible in the increasing focus on cancer therapies, autoimmune disease treatments, and personalized medicine, all of which heavily rely on biologic APIs. The Saudi government's efforts to boost local pharmaceutical manufacturing, combined with its push to foster biotechnology and innovation, will create a favorable environment for the growth of biopharmaceutical API production in the Kingdom.
Adoption of Advanced Manufacturing Technologies (Industry 4.0)The integration of advanced manufacturing technologies, often referred to as Industry 4.0, is another trend expected to drive the future growth of the Saudi API market. Industry 4.0 encompasses the use of automation, artificial intelligence (AI), machine learning, the Internet of Things (IoT), and big data analytics to optimize manufacturing processes, enhance quality control, and reduce operational costs.Moreover, Industry 4.0 technologies enable the production of more complex APIs, such as those required for biologics and high-potency drugs, further enhancing the Kingdom's ability to meet growing demand for advanced pharmaceutical products.
Key Attributes:
Report Attribute
Details
No. of Pages
80
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$290.75 Million
Forecasted Market Value (USD) by 2030
$417.62 Million
Compound Annual Growth Rate
6.1%
Regions Covered
Saudi Arabia
Key Topics Covered: 1. Service Overview1.1. Market Definition1.2. Scope of the Market1.2.1. Markets Covered1.2.2. Years Considered for Study1.2.3. Key Market Segmentations2. Research Methodology2.1. Objective of the Study2.2. Baseline Methodology2.3. Key Industry Partners2.4. Major Association and Secondary Sources2.5. Forecasting Methodology2.6. Data Triangulation & Validation2.7. Assumptions and Limitations3. Executive Summary3.1. Overview of the Market3.2. Overview of Key Market Segmentations3.3. Overview of Key Market Players3.4. Overview of Key Regions/Countries3.5. Overview of Market Drivers, Challenges, Trends4. Voice of Customer5. Saudi Arabia Active Pharmaceutical Ingredients Market Outlook5.1. Market Size & Forecast5.1.1. By Value5.2. Market Share & Forecast5.2.1. By Type of Synthesis (Synthetic, Biotech, Monoclonal Antibodies, Recombinant Proteins, Vaccines, Hormones, Cytokines, Therapeutic Enzymes, Blood Factors)5.2.2. By Type of Manufacturer (Captive APIs, Merchant APIs, Biotech Merchant APIs, Synthetic Merchant APIs)5.2.3. By Type (Generic APIs, Innovative APIs)5.2.4. By Application (Cardiovascular Diseases, Oncology, CNS and Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Others)5.2.5. By Type of Drugs (Prescription, OTC)5.2.6. By Region5.2.7. By Company (2024)5.3. Market Map6. Eastern Saudi Arabia Active Pharmaceutical Ingredients Market Outlook6.1. Market Size & Forecast6.1.1. By Value6.2. Market Share & Forecast6.2.1. By Type of Synthesis6.2.2. By Type of Manufacturer6.2.3. By Type6.2.4. By Application6.2.5. By Type of Drugs7. Western Saudi Arabia Active Pharmaceutical Ingredients Market Outlook8. Northern & Central Saudi Arabia Active Pharmaceutical Ingredients Market Outlook9. Southern Saudi Arabia Active Pharmaceutical Ingredients Market Outlook10. Market Dynamics10.1. Drivers10.2. Challenges11. Market Trends & Developments11.1. Recent Developments11.2. Product Launches11.3. Mergers & Acquisitions12. Saudi Arabia Active Pharmaceutical Ingredients Market: SWOT Analysis13. Competitive Landscape
Pfizer Scientific Technical Limited Company
Aurobindo Pharma Limited
Novartis AG
BASF Saudi Arabia Co. Ltd.
Viatris Inc
Novo Nordisk Saudi Arabia
For more information about this report visit https://www.researchandmarkets.com/r/4vnz66
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Saudi Arabian Active Pharmaceutical Ingredients Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Tech shares climb after strong Nvidia results despite warning over rise of Chinese rivals
Technology shares climbed on Thursday, buoyed by strong results from Nvidia, despite the AI chip company's boss issuing a warning about the rise of Chinese rivals. The Stoxx Europe tech index rose by 0.8% on Thursday following Nvidia's financial report, with the Dutch semiconductor equipment maker ASML rallying by 2.4%. In the US, futures for the tech-focused Nasdaq climbed 2%, and shares in Nvidia itself jumped 6% in pre-market trading. The boost to tech and artificial intelligence stocks came hours after Nvidia beat Wall Street forecasts, with quarterly revenues jumping 69% to $44bn (£32.6bn). The company also said it expected deals in the Middle East to start to fill a gap left by the loss of Chinese business. In April the US president, Donald Trump, said he was restricting AI chip exports to China, in effect barring Nvidia from selling its H20 AI chips to Chinese companies and blocking a major source of its revenue. Nvidia's chief executive, Jensen Huang, warned that Chinese rivals were benefiting from the void left by US firms forced to abandon the market due to US trade restrictions. 'The Chinese competitors have evolved,' Huang told Bloomberg Television. He added that Huawei, which had been blacklisted by the US government, had become 'quite formidable'. 'Like everybody else, they are doubling, quadrupling capabilities every year,' Huang said. 'And the volume is increasing substantially.' While the US government policy is meant to keep AI technologies out of the hands of Chinese actors, Huang said local companies are simply finding other options. 'You cannot underestimate the importance of the China market,' Huang said. 'This is the home of the world's largest population of AI researchers.' Nvidia said it expects to miss out on $8bn in revenue in the second quarter as a result of Trump's trade restrictions. Tech investors were also optimistic after a US trade court ruled against Trump's sweeping tariffs regime, in a move that could ultimately block the president's sweeping trade levies. But there is further uncertainty ahead, with the White House having already filed an appeal against the decision, issued by judges from the New York-based court of international trade. Meanwhile, shares in Tesla, another leader in artificial intelligence technology, rose 2.6%, after the company's chief executive, Elon Musk, confirmed that he would formally leave his role in the Trump administration. Musk has been leading the 'department of government efficiency' (Doge) since January, which ruthlessly cut state spending across a number of public departments and agencies. He said in April he would be stepping back after seeing Tesla's earnings plunge and failing to win a supreme court race in which he spent millions of dollars supporting a Republican candidate. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Which career in Europe will reward you with the highest salary?
Salaries vary widely across sectors and professions in Europe. While a number of jobs are disappearing, new ones are also emerging. Some roles, like those in healthcare, continue to be essential. So, which sectors offer the highest pay in Europe? And what are the top-earning jobs? Exploring these questions can help when choosing a career — though salary may not be the main driver for everyone. Euronews Business analyses the highest-paying roles in Europe, using data shared by the global hiring platform Indeed with our journalists. The analysis covers four countries (the UK, Germany, France and the Netherlands) and the salary data reflects annual earnings from May 2024 to April 2025. The occupation 'physicians and surgeons' is excluded from the main dataset, prompting a separate analysis. Medical consultants, radiologists, medical directors, orthodontists, and dentists are consistently among the highest-paid roles across all countries. These jobs appear in categories including: medical technician, medical information, nursing, and dental. This is especially true in the UK, where nearly half of the top 20 highest-paying jobs fall under these brackets. In France, three of the top four highest-paying jobs are also in these categories — particularly dental roles. Titles such as managing director, director of strategy, project director, and director of technology are well compensated across countries. These positions are found in sectors like sales, banking and finance, technology, and general management, indicating that leadership roles tend to carry premium compensation in many industries. Related Where did real wages rise and fall the most in Europe in 2024? Which countries have the highest and lowest pensions in Europe? Roles in software development, information design and documentation, and IT operations — like software engineer, data engineer, and SAP consultant — are well-paid, particularly in Germany and the Netherlands. While entry-level sales roles are less lucrative, senior roles like sales director, head of sales, and enterprise account executive show high earning potential. These roles often come with large pay packages in Germany and the Netherlands, where experienced sales professionals can earn salaries comparable to those seen in tech or management roles. Positions like tax director, labour law attorney (or an employment solicitor), and financial controller are consistently high-paying, particularly in Germany and the UK. These roles fall under legal, accounting, and banking and finance categories and reward deep regulatory or financial expertise. Job skills are constantly evolving, especially with advancements in technology. 'Continuous learning is essential in a fast-evolving market,' Pawel Adrjan, Director of Economic Research at Indeed, told Euronews Business. 'As was the case with all prior cases of technological innovations, professionals who proactively learn new tools, platforms, and methodologies will position themselves more competitively to work most efficiently with the emerging technologies.' In Germany, corporate tax advisors receive the highest annual median salary, at €145,000. The chart also displays mean salaries for comparison. Various sales roles, such as managing director and head of sales, follow closely, with median earnings ranging from €107,500 to €138,243. A labour law attorney earns €105,000, while a lawyer receives €93,334. System applications product (SAP) consultants earn just below the €100,000 threshold, with senior system engineers close behind at €95,000. Other tech roles such as IT security specialist and technical SAP consultant make around €90,000. In the management category, directors also earn approximately €90,000. There is only one medical title listed — dentists — earning a median salary of nearly €86,000. In France, dentists top the list with the highest annual median salary at €95,000, followed by orthodontists earning €78,750. In the tech sector, network architects receive €72,361, while medical technicians in the healthcare field make €70,000. A compliance officer in production and manufacturing earns €67,500. Roles like domain manager and sales agent follow, with salaries of around €65,000 and €64,855 respectively. The digital transformation consultant and mechanical designer earn €62,750 and €62,500. Several positions report identical median salaries of €60,000, including engineering director, real estate salesperson, operations director, senior sales representative, account executive, production director, human resources director, cloud architect (cloud IT professional) and loan broker advisor. Healthcare professions dominate the top end of the UK salary spectrum, with nine of the top 20 highest-paying roles in this sector. In the UK, fashion models top the list with a striking annual median salary of €166,390 (£140,000). They are followed by medical consultants, earning €145,821 (£111,412). Medical directors and radiologists both earn €137,566. Other high earners in the healthcare sector include orthodontists (€130,767), clinical consultants (€125,392), chief nursing officers (€124,793), and clinical directors (€109,442). Associate dentists (€116,785) and periodontists (€113,808) are also among the top earners. In sterling, their annual salaries range from £96,000 to £116,000. Senior leadership and technical roles also feature prominently: project directors earn €122,528, directors of technology €121,821, and microbiologists €121,313. In the Netherlands, roles in management, accounting, and software development are among the best-paid. General directors lead with a median annual salary of €115,000. Other top-paying roles include business controllers (€80,000), team leaders (€78,206), and engineers (€75,208). Finance roles like controllers and financial controllers also perform well, earning between €72,500 and €75,816. Salaries in sales and tech positions tend to cluster between €56,500 and €66,000, with roles such as sales manager, software engineer, data analyst, and account executive all falling within this range. 'Attending a top-ranked university can certainly influence job prospects and salary potential, especially in countries like France or the UK,' Pawel Adrjan said. He noted that graduating from elite educational institutions like grandes écoles and universities with a long history can be perceived as a signal of ability in the labour market. 'However, recent trends we observe on Indeed in both the UK and France show that formal education requirements in job postings are becoming less common, especially in high-skill fields like IT and data science, suggesting a gradual shift toward skills-based hiring,' he added. As jobs continue to evolve, it's completely natural for the highest-paying roles to change too. 'Over the next 5-10 years, we anticipate that green energy, AI/GenAI, cybersecurity, and biotechnology will produce new top-earning job titles,' said Adrjan of Indeed. He explained that roles like AI ethicist, key sustainability roles, GenAI engineers, and climate data analysts are gaining traction and are likely to move into the upper salary echelons as demand for specialised expertise in these areas grows. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
What the UK's Emergency Services Can Teach Startups About AI That Actually Works -- New Report from Speechmatics
New report reveals how Voice AI is quietly transforming frontline response while others scale back CAMBRIDGE, England, June 03, 2025--(BUSINESS WIRE)--While many "AI-first" launches have fizzled, emergency services are showing what it really means to put AI to work. A new report from Speechmatics reveals that 100% of UK ambulance calls now run through Voice AI infrastructure. Titled The Voice AI Reality Check: Frontline Perspectives for Enterprise in 2025, the report explores how speech systems are quietly transforming high-pressure environments like triage, crisis response and public service contact centres. Forget avatars and demos — real-world adoption is being driven by accuracy, speed, and reliability. Key findings include: Full Voice AI coverage across UK ambulance services 40% clinician time reclaimed in public healthcare settings 93% satisfaction using voice-led systems in utilities Hybrid deployments (on-prem, cloud, edge) now expected as standard Speech AI technology sits behind these critical deployments — enabling real-time transcription, multilingual support, and data privacy at scale. As enterprises rethink their AI strategies, this report highlights the sectors already making it work — and what others can learn from them. Download the full report now. View source version on Contacts For interviews, images, quotes or media access, contact: Mieke Kyra, Content Lead Sign in to access your portfolio
